Allergy Therapeutics plc
AGY
Rank in Stocks
#19364
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and... Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Share Price
$0.01713721
Last synced: 2026-11-09
Market Cap
$108.52M
Change (1 day)
0.59%
Change (1 year)
-84.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Allergy Therapeutics plc (AGY)
Category
Healthcare
Operating Margin for Allergy Therapeutics plc (AGY)
Operating Margin as of November 2026 TTM: -60.23%
According to Allergy Therapeutics plc's latest financial reports, its current operating margin (TTM) is -60.23%. At the end of 2025 the company had an operating margin of -53.60%.
Operating Margin history for Allergy Therapeutics plc from 2002 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -60.23% | 12.37% |
| 2025 | -53.60% | -16.08% |
| 2024 | -63.87% | 9.20% |
| 2023 | -58.49% | 227.31% |
| 2022 | -17.87% | -473.85% |
| 2021 | 4.78% | -16.14% |
| 2020 | 5.70% | -328.92% |
| 2019 | -2.49% | -74.62% |
| 2018 | -9.81% | 217.48% |
| 2017 | -3.09% | -87.64% |
| 2016 | -24.99% | -1,561.40% |
| 2015 | 1.71% | -28.45% |
| 2014 | 2.39% | 40.59% |
| 2013 | 1.70% | -35.85% |
| 2012 | 2.65% | 846.43% |
| 2011 | 0.28% | -92.16% |
| 2010 | 3.57% | -73.59% |
| 2009 | 13.52% | -73.10% |
| 2008 | 50.26% | -50.76% |
| 2007 | 102.07% | 258.14% |
| 2006 | 28.50% | 142.97% |
| 2005 | 11.73% | 35.76% |
| 2004 | 8.64% | -195.58% |
| 2003 | -9.04% | -132.19% |
| 2002 | 28.08% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.32% |
DE
|
|
| 19.68% | -100.33% |
DE
|
|
| 13.26% | -100.22% |
JP
|
|
| 17.08% | -100.28% |
CH
|
|
| 14.92% | -100.25% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Allergy Therapeutics plc's operating margin
What is Allergy Therapeutics plc's operating margin?
Allergy Therapeutics plc's operating margin is -60.23%, as of Nov 2026.
What was Allergy Therapeutics plc's operating margin in 2025?
In 2025, Allergy Therapeutics plc's operating margin was -53.60%, compared with -63.87% in 2024.
How has Allergy Therapeutics plc's operating margin changed since 2020?
From 2020 to 2025, Allergy Therapeutics plc's operating margin was highest in 2020 (5.70%) and lowest in 2024 (-63.87%).
How does Allergy Therapeutics plc's operating margin compare with similar companies?
Allergy Therapeutics plc's operating margin (-60.23%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.